Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
The development of fibrosis in the chronically hypertensive heart is associated with infiltration of inflammatory cells and cardiac hypertrophy. In this study, an inhibitor of the proinflammatory enzyme, group IIA human secretory phospholipase A2 (sPLA2-IIA), has been found to prevent collagen deposition as an important component of cardiovascular remodeling in a rat model of developing chronic hypertension. Daily treatment of young male spontaneously hypertensive rats (SHR) with an sPLA2-IIA inhibitor (KH064, 5-(4-benzyloxyphenyl)-4S-(phenyl-heptanoylamino)-pentanoic acid, 5 mg/kg/day p.o.) prevented increases in the content of perivascular (SHR 20.6 +/- 0.9%, n = 5; SHR+KH064 14.0 +/- 1.2%, n = 5) and interstitial (SHR 7.9 +/- 0.3%, n = 6; SHR+KH064 5.4 +/- 0.7%, n = 6) collagen in the left ventricle of rat hearts, but did not affect numbers of infiltrating monocytes/macrophages, left ventricular hypertrophy (SHR 2.88 +/- 0.08, n = 12; SHR+KH064 3.09 +/- 0.08 mg/g body weight, n = 9), increased systolic blood pressure, or thoracic aortic responses. This selective antifibrotic activity suggests that sPLA2-IIA may have an important but specific role in cardiac fibrosis, and that its inhibitors could be useful in dissecting molecular pathways leading to fibrotic conditions.
Levick
Scott
S
Department of Physiology and Pharmacology, School of Biomedical Sciences, University of Queensland, Brisbane, Australia.
Loch
David
D
Rolfe
Barbara
B
Reid
Robert C
RC
Fairlie
David P
DP
Taylor
Stephen M
SM
Brown
Lindsay
L
D000199:Actins / Q000378:metabolism; D000367:Age Factors; D000818:Animals; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D003094:Collagen / Q000037:antagonists & inhibitors / Q000378:metabolism; D004452:Echocardiography; D004719:Endomyocardial Fibrosis / Q000201:enzymology* / Q000503:physiopathology / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D054501:Group II Phospholipases A2; D006973:Hypertension / Q000201:enzymology* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D008264:Macrophages / Q000473:pathology; D008297:Male; D009000:Monocytes / Q000473:pathology; D009929:Organ Size / Q000187:drug effects / Q000502:physiology; D010421:Pentanoic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000502:physiology; D054467:Phospholipases A2; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY
C503211:5-(4-benzyloxyphenyl)-4S-(7-phenylheptanoylamino)pentanoic acid; D000199:Actins; D004791:Enzyme Inhibitors; D010421:Pentanoic Acids; D003094:Collagen; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2